You are here

Immunology & Inflammation

Immunology & Inflammation


Our goal is to transform chronic inflammatory diseases, many of which are poorly managed by existing treatments that only provide symptom relief, at best. We seek to address the root cause of this inflammation at a molecular level and develop first-in-class or best-in-class medicines.  We continue to advance Pfizer’s leading science on the JAK pathway, developing tailored therapies targeting specific aspects of the JAK pathway in key autoimmune diseases such as lupus.

Pfizer is also advancing programs targeting inflammation in the lung and kidneys, where environmental or internal “danger signals” in the body trigger inflammatory responses that can lead to chronic kidney disease, chronic obstructive pulmonary disease (COPD). Key to our approach is re-engaging the body’s innate immunity and key pathways of tissue remodeling and fibrosis.

Longer-term, we are increasingly studying the potential to reset immune system homeostasis by targeting immunoregulation.

Work with Us

If you’re interested in collaborating with our Inflammation and Immunology teams, visit our Immunoscience Partnering and Inflammation & Remodeling pages to learn more about the work we’re pursuing. 

Immunology & Inflammation Pipeline in Focus

Pipeline in Focus

Pfizer’s clinical stage pipeline includes two monoclonal antibodies for inflammatory bowel disease (IBD) – including Crohn’s disease and ulcerative colitis. We also have ongoing clinical trials in psoriasis, lupus, chronic kidney disease and chronic obstructive pulmonary disease (COPD).

Pfizer's Inflammation and Immunology R&D

Pfizer’s Inflammation and Immunology R&D

Pfizer is building on our heritage of breakthrough treatments in inflammation with the goal of developing first-in-class or best-in-class therapies to improve the quality of life of people living with inflammatory and autoimmune diseases.

The Challenges of Autoimmune Diseases

Hear Pfizer colleague Theresa DeSalvo-Gable share her story about living with two autoimmune diseases.